RESEARCH STUDIES & Clinical Trials

Clinical Trial ID: NCT02445391 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Status

Open

Description

This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

Objective

To compare the IDFS in TNBC patients with residual basal-like disease after neoadjuvant chemotherapy who are randomized to post-preoperative platinum based chemotherapy with those who are randomized to capecitabine.

Treatment

Experimental: Cisplatin or Carboplatin Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Experimental: Capecitabine Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Conditions

Breast

Phases

III

Therapies

Drugs

Age Group

Adult

Main Investiagtor

Crozier, Jennifer

Practice

Breast

Scope

National

Participating Institutions

Baptist MD Anderson Cancer Center

Eligibility

Eligibility Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 2 weeks prior to screening - Patients must have completed neoadjuvant taxane +/- anthracycline; patients must NOT have received cisplatin or carboplatin or capecitabine as part of their neoadjuvant therapy regimen - Must have completed definitive resection of primary tumor - Post neoadjuvant chemotherapy, patients must be found to have residual invasive cancer in the breast at the time of definitive surgery; residual cancer is defined as a contiguous focus of residual invasive cancer, in the breast, measuring >= 1 cm in diameter, and with more than minimal cellularity, as per local pathologist determination; this is required due to constraints in deoxyribonucleic acid (DNA) extraction for PAM50 analysis - Radiotherapy may be given before or after protocol treatment per standard of care guidelines; when radiotherapy is planned prior to protocol treatment administration, patients may be registered and screened while receiving radiation - Hemoglobin (Hgb) > 9.0 g/dL - Platelets > 100,000 mm^3 - Absolute neutrophil count (ANC) > 1500 mm^3 - Calculated creatinine clearance of > 50 mL/min using the Cockcroft-Gault formula - Bilirubin =< 1.5 x ULN upper limit of normal (except in patients with documented Gilbert?s disease, who must have a total bilirubin =< 3.0 mg/dL) - Aspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x upper limit of normal (ULN) - Alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN - No history of TNBC invasive breast cancer within 5 years of enrollment, no concurrent malignancies of any sort - No clinically significant infections as judged by the treating investigator - Patients with active >= Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4 grade 2 neuropathy are ineligible - Adjuvant chemotherapy after surgery other than that specified in this protocol is not allowed; luteinizing hormone-releasing hormone (LHRH) agonists and adjuvant bisphosphonate or denosumab use is allowed - Patients must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen from the residual disease on the definitive surgical specimen available for PAM50 analysis for stratification - Other criteria may apply for Step 1 Randomization

Nct ID Number

NCT02445391

Secondary Trial ID Number

EA1131

Keywords

Treatment

More Information

clinicaltrials.gov

“The support team gave not only me but my family a sense of peace.”

—David Smith, Patient

At Baptist MD Anderson, you can rely on our cancer experts to deliver the complex, coordinated care needed to address your condition. Learn more about Patricia’s story as well as others from our patients.